Sponsored news: Get to know Croma-Pharma
Croma-Pharma GmbH is an international pharmaceutical company based in Leobendorf, Austria. For over 40 years, Croma has been developing and producing innovative drugs and medical devices for the fields of ophthalmology, orthopedics and aesthetic dermatology.
Croma is very proud to have made such an important contribution to improving health and quality of life for more than four decades. Founded in 1976 by pharmacist Gerhard Prinz, Croma is now managed by his sons Martin and Andreas Prinz.
Since 2005, the company has been driven forward through rapid internationalisation. In 2014, the strategic sale of the ophthalmology and orthopedics divisions took place; since then the company has specialised in minimally-invasive aesthetic medicine. Currently, Croma has 12 international offices in Brazil, the European Union and Switzerland, and nearly 500 employees worldwide.
Croma today
Croma is a global player in the dynamically growing segment of minimally-invasive aesthetic medicine and is a leading European processor of hyaluronic acid. The company sells nearly six million hyaluronic acid syringes (injectables) annually through affiliates and a network of strategic partnerships and distributors in more than 70 countries.
Production takes place exclusively at the company headquarters in Leobendorf near Vienna, Austria. Besides a broad range of HA fillers from its own production site, Croma markets PDO lifting threads, a platelet rich plasma (PRP) system and a personalised skincare technology in its core strategic markets.
Croma is investing heavily in in-house research and development of new products to drive the company’s long-term growth through innovation. In this context, Croma also promotes medical and pharmaceutical research in Austria. Today, more than 90% of sales are generated from products of our own research.
Minimally-invasive aesthetic medicine has above-average growth potential in the global beauty market. In this area, Croma offers a steadily-growing, well-coordinated portfolio of products. The goal is a “full-face approach” to offer doctors and patients the best solutions for all indications from a single source in familiar and reliable quality.
Global expansion
In September 2018, Croma established a joint venture company with its long-time partner Hugel, Inc. to develop and commercialise botulinum toxin, HA filler and PDO thread products in the US, Canada, Australia and New Zealand.
Thus, Croma unites its development and marketing activities with a strong partner in order to prepare and implement the successful market entry. The strategic partnership with Hugel will continue Croma‘s international expansion efforts and further strengthen its market position.
Asia in general and China in particular are outperforming markets in aesthetic medicine. In May 2017, the dermal filler Princess VOLUME was approved in China by the CFDA. Croma-Pharma was the first European company to do so. Almost at the same time, the company signed with Sihuan Pharma Ltd. a long-standing license and distribution agreement.
This joint venture with the third-largest Chinese pharmaceutical company is aimed at the approval of further products and the nationwide distribution of these products in mainland China.
For more information on Croma and its product portfolio click here or contact [email protected]
Sponsored news